Funding for COVID 2.0 under way as Project NextGen spends more than $1.4 billion to develop new “vaccines,” therapeutics

If you thought the Wuhan coronavirus (COVID-19) was over, think again.

The regime of fake president Joe Biden is spending another $1.4 billion on a program called Project NextGen that aims to develop new “vaccines” and other “therapeutics” for the never-ending stream of new COVID “variants” and “subvariants.”

According to an announcement from the Department of Health and Human Services (HHS), the multi-billion-dollar taxpayer-funded initiative will funnel lots of cash into the coffers of the government’s “industry partners,” which include Big Pharma corporations like Pfizer.

Project NextGen will pour lots of money into clinical trials for new COVID drugs including “more effective and longer-lasting coronavirus vaccines, a new monoclonal antibody, and transformative technologies to streamline manufacturing processes.”

HHS Secretary Xavier Becerra boasted proudly about the launch of Project NextGen, stating that it is the brainchild of the Biden-Harris regime’s “commitment to keeping people safe from COVID-19 variants.”

“These awards are a catalyst for the program – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”

(Related: Check out these 10 obvious lessons everyone should have learned from the first round of COVID.)

America: Are you really okay with your government spending your hard-earned dollars on more COVID poisons?

The full scope of Project NextGen includes $5 billion in funding from ASPR’s Biomedical Advanced Research and Development Authority (BARDA) in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), formerly headed up by Tony Fauci.

In essence, the project is a public-private partnership in which the federal government, using American tax dollars, pays Big Pharma to develop new drugs and other interventions for every new strain of COVID that comes down the pike.

“For years to come,” says HHS, there will be one new COVID “vaccine” after another, thanks to this large cash pile.

“As the virus continues to evolve, we need new tools that keep pace with those changes,” said Assistant Secretary for Preparedness and Response Dawn O’Connell.

“Project NextGen combines the research and development expertise at HHS with the lessons we have learned about the virus throughout the pandemic – strengthening our preparedness for whatever comes next.”

Among the BARDA Clinical Trial partners who will partake of $1 billion in taxpayer funding to support “vaccine” Phase IIb clinical trial studies are:

• ICON Government and Public Health Solutions, Inc of Hinckley, Ohio
• Pharm-Olam, LLC, of Houston, Texas
• Technical Resources Intl (TRI), Inc, of Bethesda, Maryland
• Rho Federal Systems, Inc., Durham, North Carolina

Another $326 million will go to Regeneron to develop another monoclonal antibody “passive vaccination” protocol, while $100 million will go to the Global Health Investment Corp. (GHIC) to expand investment in new technologies that will accelerate the development and release of new drugs at warp speed.

Johnson & Johnson will also partake of $10 million for BLUE KNIGHT, a Project NextGen accelerator.

The goal of all this is to maintain a steady pipeline of new COVID injections to be released as fast as possible so the profits keep flowing into the bank accounts of Big Pharma companies. This is all about money and depopulation, in other words.

“COVID 1.0 was just a test run to see how people would comply or not comply,” one commenter wrote about how COVID 2.0, which is what Project NextGen is designed to unleash, will be a whole lot worse.

“The propaganda and brainwashing of the masses are very powerful. And if they tell a lie long enough, people will believe it. They are relying on people being stupid. To follow mad scientists and their mad science, one would have to be insane.”

What do you think the COVID 2.0 “pandemic” will look like? Learn more about what is coming at Plague.info.

Sources for this article include:

HHS.gov

NaturalNews.com